The latest news from Retina UK. Please use the filters to find the articles which interest you.

In April 2022 we joined with another seven leading sight loss organisations to make a public commitment to increasing the number of blind and partially sighted people employed within our sector, including at senior management level.

In February 2022, ProQR announced a disappointing outcome for their phase 2/3 trial of sepofarsen for Leber congenital amaurosis type 10 (LCA10).

A megaphone with the words 'make your voice heard. Complete the Retina UK sight loss survey'

Help to shape our future

Would you like to help shape Retina UK’s future? Do you want to ensure decision-makers understand the impact of inherited sight loss? If so we’d love to hear from you.

You may have heard that a cell-based treatment approach (sometimes referred to as a “stem cell treatment”), developed by a company called ReNeuron, is being tested in a clinical trial at Oxford Eye Hospital and other centres in the US and Europe.